£50.00
Tesamorelin 10mg — lyophilised research peptide, ≥99% purity, supplied as a white powder in a sealed vial. A stabilised synthetic analogue of growth hormone-releasing hormone (GHRH), studied for its role in pituitary GH secretion, IGF-1 signalling, and visceral adipose tissue regulation. Certificate of Analysis available. For research use only. UK-based supplier.
25 people are viewing this product right now
Tesamorelin 10mg is a lyophilised research peptide supplied as a white to off-white powder in a sealed, nitrogen-purged vial. A stabilised synthetic analogue of human growth hormone-releasing hormone (GHRH), Tesamorelin 10mg consists of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid moiety conjugated to the N-terminus, increasing plasma half-life and resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage. Arma Peptides supplies Tesamorelin 10mg at ≥99% purity, confirmed by third-party HPLC and mass spectrometry. Full batch CoA documentation is available on our Certificate of Analysis page. For research use only.
Tesamorelin is a synthetic GHRH analogue developed to study the hypothalamic-pituitary axis and endogenous growth hormone regulation. It binds selectively to pituitary GHRH receptors, stimulating pulsatile GH secretion and downstream IGF-1 production. Unlike exogenous recombinant GH, Tesamorelin acts through physiological feedback mechanisms, preserving the natural pulsatile pattern of GH release. Its molecular formula is C₂₂₃H₃₇₀N₇₂O₆₉S with a molecular weight of approximately 5,196 g/mol. Full compound data is available via the PubChem entry for Tesamorelin (CID 16137828). The compound is also catalogued on ChEMBL as CHEMBL1237026.
Tesamorelin binds to growth hormone-releasing hormone receptors (GHRHR) expressed on somatotroph cells in the anterior pituitary. Receptor activation triggers intracellular cAMP accumulation via Gs protein coupling, leading to GH synthesis and secretion. Released GH subsequently stimulates hepatic IGF-1 production, which mediates downstream anabolic and metabolic effects. Because Tesamorelin acts upstream of GH itself, the normal negative feedback loop through somatostatin remains intact — a key advantage for preclinical mechanistic studies compared to direct GH administration.
Tesamorelin 10mg is used across several areas of preclinical and translational research:
Key published research includes a PMC study on the effects of a GHRH analogue on endogenous GH pulsatility (PMC3038486), which provides mechanistic context for Tesamorelin’s pituitary activity in experimental settings.
| Parameter | Specification |
|---|---|
| Peptide | Tesamorelin (GHRH analogue) |
| Amount | 10mg per vial |
| Form | Lyophilised powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified) |
| Molecular Formula | C₂₂₃H₃₇₀N₇₂O₆₉S |
| Molecular Weight | ~5,196 g/mol |
| CAS Number | 218949-48-5 |
| Storage | −20°C, away from moisture and light |
| Usage | Research use only |
Every batch of Tesamorelin 10mg supplied by Arma Peptides is independently tested before dispatch. Purity is confirmed at ≥99% by HPLC with identity verification by mass spectrometry. Batch-specific certificates are published on our laboratory tests page. We do not release stock without passing quality thresholds.
Store lyophilised Tesamorelin 10mg at −20°C in a dry, dark environment. Avoid freeze-thaw cycling to maintain peptide integrity. For in vitro reconstitution, use sterile aqueous buffer appropriate to the assay and aliquot immediately. Store reconstituted working solutions at −80°C for short-term use.
Researchers studying the GH axis and peptide secretagogues often pair Tesamorelin 10mg with complementary compounds. Browse related products available from Arma Peptides:
This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for resale. Must be handled by qualified researchers in appropriate laboratory conditions.
£25.00
£30.00
Reviews
There are no reviews yet.